Enzalutamide inhibits androgen receptor–positive bladder cancer cell growth

Medicine and Dentistry

• Androgen Receptor 73%
• Bladder Cancer 47%
• Androgen 31%
• Enzalutamide 31%
• Androgen Receptor Antagonist 26%
• Cancer Cell 15%
• Cell Migration 15%
• Assay 15%
• Cell Invasion 15%
• Cancer Growth 15%
• Androstanolone 15%
• Cells 10%
• Therapeutic Procedure 10%
• Cell Proliferation 10%
• Short Hairpin RNA 10%
• Growth 10%
• Tumor Progression 10%
• Xenograft 10%
• Antiandrogen 10%
• Bicalutamide 10%
• Real Time Polymerase Chain Reaction 5%
• Combination Therapy 5%
• Programmed Cell Death 5%
• Flow Cytometry 5%
• Observation 5%
• Interleukin 6 5%
• Cell Viability 5%
• Feeding 5%
• Reporter Gene 5%
• Wound Healing 5%
• Gelatinase A 5%
• Flutamide 5%
• Hydroxyflutamide 5%
• Cell Viability Assay 5%

Biochemistry, Genetics and Molecular Biology

• Androgen Receptor 100%
• Enzalutamide 31%
• Growth 26%
• Receptor Antagonist 26%
• Cancer Cell 21%
• Cell Migration 15%
• Cell Invasion 15%
• Mouse 10%
• RNA 10%
• Cell Proliferation 10%
• Agonist 10%
• Cell Viability 10%
• Bicalutamide 10%
• Real-Time Polymerase Chain Reaction 5%
• Interleukin 6 5%
• Apoptosis 5%
• Matrix Metalloproteinase 5%
• Cell Growth 5%
• Reporter Gene 5%
• Flow Cytometry 5%
• Wound Healing Assay 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Androgen Receptor 73%
• Bladder Cancer 47%
• Enzalutamide 31%
• Androgen 31%
• Androgen Receptor Antagonist 26%
• Agonist 21%
• Cancer Growth 15%
• Androstanolone 15%
• Mouse 10%
• Tumor Growth 10%
• Antiandrogen 10%
• Short Hairpin RNA 10%
• Bicalutamide 10%
• Interleukin 6 5%
• Gelatinase A 5%
• Flutamide 5%
• Wound Healing 5%
• Hydroxyflutamide 5%